S9333A Study of Blood and Bone Marrow Samples From Patients With Previously Untreated Primary Acute Myeloid Leukemia
RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at blood and bone marrow samples from patients with previously untreated primary acute myeloid leukemia.
|Leukemia||Genetic: polyacrylamide gel electrophoresis Genetic: western blotting Other: immunologic technique Other: laboratory biomarker analysis|
|Study Design:||Time Perspective: Retrospective|
|Official Title:||Determining the Clinicopathological Significance of CaMKIIgamma Activation in AML|
- Association of specific clinicopathological variables and outcomes with calmodulin-dependent protein kinase II-γ (CaMKIIγ) activation (autophosphorylation) [ Time Frame: upon receipt of specimens ]
|Study Start Date:||August 2008|
|Study Completion Date:||June 2009|
|Primary Completion Date:||June 2009 (Final data collection date for primary outcome measure)|
Genetic: polyacrylamide gel electrophoresis
- Determine whether calmodulin-dependent protein kinase II-γ (CaMKIIγ) activation (autophosphorylation) is associated with specific clinicopathological variables and outcomes in blood and bone marrow samples from patients with previously untreated primary acute myeloid leukemia.
OUTLINE: Blood and bone marrow samples are analyzed by western blot using SDS-PAGE and immunoblotting using anti-calmodulin-dependent protein kinase II-γ (CaMKIIγ) and anti-phosphospecific (Thr286, 287) CaMKIIγ antibodies with signals detected via chemiluminescence. CaMKIIγ activation levels are linked to clinical variables within the SWOG database.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00899743
|Principal Investigator:||Steven J. Collins, MD||Fred Hutchinson Cancer Research Center|